
SUPERIOR HEMODYNAMICS

Evolut TAVI Platform
Evolut™ TAVI is currently the only TAVI device to demonstrate hemodynamic superiority in a low risk clinical trial vs. SAVR at one year.1
LEARN ABOUT EVOLUT LOW RISK STUDY RESULTS FROM NEJMSUPERIOR
EFFECTIVE ORIFICE AREAS
(EOA)
Evolut TAVI 2.3 cm2 vs. SAVR 2.0 cm2
15% Larger EOAs

SUPERIOR Gradients
Evolut TAVI 8.6 mm Hg vs. SAVR 11.2 mm Hg
23% Lower Gradients

SAFE and EFFECTIVE
As demonstrated by all-cause mortality or disabling stroke, noninferior to SAVR at 24 months1
5.3% TAVI vs. 6.7% SAVR
n = 1,468

Evolut TAVI compared to SAVR
EvolutTM TAVI showed lower mortality, fewer disabling strokes, and fewer heart failure rehospitalisations compared to SAVR2

FASTER RETURN TO AN ACTIVE LIFE
- EVOLUT TAVI SUPERIOR TO SAVR
in self-reported KCCQ measures at 30 days1
- 58% SHORTER HOSPITAL STAY
with TAVI procedures vs. SAVR procedures2
- LOWER RATES OF HEART FAILURE REHOSPITALIZATION
with Evolut TAVI vs. SAVR at one year2

References
Popma JJ, Deeb GM, Yakubov SJ, et al. Transcatheter Aortic-Valve Replacement with a Self-Expanding Valve in Low-Risk Patients. N Engl J Med. May 2, 2019;380(18):1706-1715.
Reardon MJ. The Evolut Low Risk Trial. Presented at ACC 2019; New Orleans, LA.